{'fraction_non_alphanumeric': 0.02756892230576441, 'fraction_numerical': 0.0037593984962406013, 'mean_word_length': 4.626760563380282, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.

PURPOSE
We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG).


METHODS
We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM.


RESULTS
GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw.


CONCLUSION
Our study has important implications in the care of MM, particularly in countries/areas with limited resources.